AUSTRALIA'S Generic and Biosimilar Medicines Association (GBMA) is using Global Biosimilars Week, running from 11-15 Nov, to emphasise the benefits of biosimilar medicines for patients and the economy.
Although biosimilars have improved treatment options for chronic conditions worldwide, Australia's adoption rates lag behind other OECD nations, according to GBMA's independent Chair, Prof Jane Halton.
"A single biosimilar on the PBS could save up to $100m, allowing funds to be reinvested in healthcare," said Halton.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Nov 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Nov 24
